ArticleJournal of the National Cancer Center2026
The global burden of early-onset cancer in women, 1990-2021: findings from the GBD 2021 with focus on China.
Article in Journal of the National Cancer Center, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Female cancers in adolescent and young adult women: global inequities and 2050 burden estimates from GLOBOCAN 2022.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset cancer is a significant public health threat in females, yet comprehensive data on its global burden and temporal trends remain limited. Our study aimed to provide a comprehensive assessment of global burden of female early-onset cancer from 1990 to 2021, and to project its change to 2050. Methods: This study analyzed the incidence, mortality, and disability-adjusted life years (DALYs) of female early-onset cancers (ages 15-49 years) from 1990 to 2021, with projections to 2050, using Global Burden of Disease (GBD) 2021 data. We presented absolute counts and age-standardized rates (ASRs) per 100,000 population for 31 malignancies with 95% uncertainty intervals (UIs). Estimated annual percentage changes (EAPCs) quantified temporal trends in ASRs, while Autoregressive Integrated Moving Average (ARIMA) models projected future burden. Countries were stratified by socio-demographic index (SDI) quintiles, and Spearman rank correlation analysis and Frontier analysis were used to explore the relationship between SDI and disease burden. Risk-attributable burden was assessed through GBD's comparative risk framework. Results: From 1990 to 2021, the number of global new cases of female early-onset cancers rose from 11.49 to 17.06 million, and the number of deaths increased from 0.40 million to 0.51 million. Early-onset breast cancer had the highest burden, followed by cervical cancer. Globally, the age-standardized incidence rate (ASIR) showed a slight decline with the EAPC of -0.13%, whereas the United States saw a significant rise (EAPC = 1.36%). The age-standardized mortality rate (ASMR) declined significantly (EAPC = -1.14%), with China experiencing a steep reduction (EAPC = -2.09%). Modifiable risk factors accounted for 31.44% of total deaths in 2021, concentrated in cervical (100% of its deaths attributable to modifiable risk factors), lung (50.05%), and colorectal cancers (50.85%). Projections indicated that ASIR would peak at 880.95 per 100,000 by 2027 and subsequently stabilize, while ASMR would decline to 23.74 per 100,000 by 2050. Conclusions: The findings of this study characterize the global disease burden of early-onset cancers in women, encompassing temporal trends, regional disparities, risk attribution, and future projections, further validating the significance of preventive strategies including screening. Our results provide insights for targeted preventive strategies of early-onset cancers for female populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.